MTCYBP16

Across TCGA pan-cancer cohorts, MTCYBP16 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MTCYBP16’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where MTCYBP16 RNA is repressed in tumor relative to normal tissue. In most cancer types MTCYBP16 is over-expressed in tumor, although a few such as KIRC show the opposite, repressed pattern.

KIRC, COAD, and KICH are the cancer types where MTCYBP16 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTCYBP16 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	II,III,IV	−0.072	<.001	10	view →
COAD	All	II,III,IV	+0.264	.009	5	view →
KICH	All	All	+0.068	.014	4	view →
UCEC	All	IV	+0.250	.037	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

MTCYBP16–KIRC

Open the KIRC breakdown →